Julie J.G. Kephart

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Andrew J. Armstrong, Susan Halabi, Patrick Healy et al. · European Journal of Cancer · 2017 · 93 citations · Full text

Urology, Phase Ii Trial, Medicine +6

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer

Daniel J. George, Susan Halabi, Elisabeth I. Heath et al. · Cancer · 2021 · 38 citations · Full text

Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).

Daniel J. George, Elisabeth I. Heath, Oliver Sartor et al. · Journal of Clinical Oncology · 2018 · 36 citations

Prognostic Biomarkers, Urology, Psa Pfs +14

Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer

Tian Zhang, Julie J.G. Kephart, Elizabeth Bronson et al. · The Prostate · 2022 · 22 citations

Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

Julie J.G. Kephart, Rosanne G.J. Tiller, Lisa E.S. Crose et al. · Clinical Cancer Research · 2015 · 21 citations · Full text